drugset / Trial / NCT03214406

Clinical Evaluation of the Efficacy of a Marketed Dentifrice on Plaque and Gingivitis

NCT03214406 ↗

Completed 181 enrolled Church & Dwight Company, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Parallel, double blind, randomized, Institutional Review Board (IRB) -approved study involving approximately 160 subjects to complete. Subjects were randomly assigned to either the test product (Arm \& Hammer Advance White Brilliant Sparkle) or the control (Crest Cavity Protection Regular) based on baseline mean whole-mouth plaque and gingival scores and age.Subjects brushed with their assigned dentifrice two times (2X) daily and were evaluated for gingivitis, bleeding and plaque at Baseline and after 4-, 8-, and 12-weeks of product use. Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.

Timeline

Start
2010-02-08
Primary completion
2010-08-03
Completion
2010-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Arm & Hammer Advance White Brilliant Sparkle Unknown 20 % —
Comparator Crest Cavity Protection Regular Toothpaste Unknown — —